Engineered cells as a test platform for radiohaptens in pretargeted imaging and radioimmunotherapy applications Journal Article


Authors: Dacek, M. M.; Veach, D. R.; Cheal, S. M.; Carter, L. M.; McDevitt, M. R.; Punzalan, B.; Burnes Vargas, D.; Kubik, T. Z.; Monette, S.; Santich, B. H.; Yang, G.; Ouerfelli, O.; Kesner, A. L.; Cheung, N. K. V.; Scheinberg, D. A.; Larson, S. M.; Krebs, S.
Article Title: Engineered cells as a test platform for radiohaptens in pretargeted imaging and radioimmunotherapy applications
Abstract: Pretargeted imaging and radioimmunotherapy approaches are designed to have superior targeting properties over directly targeted antibodies but impose more complex pharmacology, which hinders efforts to optimize the ligands prior to human applications. Human embryonic kidney 293T cells expressing the humanized single-chain variable fragment (scFv) C825 (huC825) with high-affinity for DOTA-haptens (293T-huC825) in a transmembrane-anchored format eliminated the requirement to use other pretargeting reagents and provided a simplified, accelerated assay of radiohapten capture while offering normalized cell surface expression of the molecular target of interest. Using binding assays, ex vivo biodistribution, and in vivo imaging, we demonstrated that radiohaptens based on benzyl-DOTA and a second generation "Proteus"DOTA-platform effectively and specifically engaged membrane-bound huC825, achieving favorable tumor-to-normal tissue uptake ratios in mice. Furthermore, [86Y]Y-DOTA-Bn predicted absorbed dose to critical organs with reasonable accuracy for both [177Lu]Lu-DOTA-Bn and [225Ac]Ac-Pr, which highlights the benefit of a dosimetry-based treatment approach. © 2021 American Chemical Society.
Journal Title: Bioconjugate Chemistry
Volume: 32
Issue: 4
ISSN: 1043-1802
Publisher: American Chemical Society  
Date Published: 2021-04-01
Start Page: 649
End Page: 654
Language: English
DOI: 10.1021/acs.bioconjchem.0c00595
PUBMED: 33819023
PROVIDER: scopus
PMCID: PMC8284561
DOI/URL:
Notes: Article -- Export Date: 1 July 2021 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Nai-Kong Cheung
    648 Cheung
  2. Michael R Mcdevitt
    144 Mcdevitt
  3. Darren Veach
    97 Veach
  4. Ouathek Ouerfelli
    100 Ouerfelli
  5. Sebastien Monette
    148 Monette
  6. Guangbin Yang
    27 Yang
  7. Steven M Larson
    958 Larson
  8. Sarah Marie Cheal
    48 Cheal
  9. Brian Horacio Santich
    18 Santich
  10. Simone Susanne Krebs
    55 Krebs
  11. Adam Leon Kesner
    68 Kesner
  12. Lukas M Carter
    79 Carter
  13. Megan Dacek
    17 Dacek
  14. Thomas Z. Kubik
    1 Kubik